Reduction of Liver Span and Parameters of Inflammation in Nonalcoholic Fatty Liver Disease Patients Treated with Lycosome Formulation of Phosphatidylcholine: A Preliminary Report

Table 3

Serum AST/ALT activity after treatment with regular and lycosome formulations of PC (medians with 95/5%% CI).

Duration of treatment	Formulations of PC
	Regular	Lycosome
	AST (IU/ml)
Baseline	38.5 (45.0/34.6)	38.0 (43.0/35.0)
1 month	40.5 (44.3/36.0)	37.5 (42.4/35.0)
2 months	39.0 (43.0/36.0)	36.0 (38.7/35.0)
	ALT (IU/ml)
Baseline	61.0 (67.3/52.9)	59.5 (68.7/54.0)
1 month	59.0 (65.3/51.6)	57.0 (66.4/51.2)
2 months	58.0 (63.3/50.6)	53.5 (60.0/47.6)

The patients were screened, enrolled, randomized, and treated with regular (PC) or lycosome (PC-Lycosome) formulations of phosphatidylcholine (PC) for 2 months as described in Materials and Methods. Median values with confidence intervals for AST and ALT activity at time “0” and the end point of the study are shown above; as compared to baseline.